Supplementary Figure S5 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial

Holger N. Lode; Nikolai Siebert; Dominique Valteau‐Couanet; Alberto Garaventa; Adela Cañete; John W. Anderson; Isaac Yaniv; Shifra Ash; Juliet C. Gray; Thomas Klingebiel; Hans Loibner; Roberto Luksch; Carla Manzitti; Jean Michon; Cormac Owens; Ulrike Pötschger; Sascha Troschke‐Meurer; Evgenia Glogova; Ruth Ladenstein

doi:10.1158/1078-0432.30028886

Key Points

HACA-positive patients experienced different survival outcomes compared to HACA-negative patients.
The area under the curve (AUC) of dinutuximab beta exposure impacts overall survival rates significantly.
Event-free survival rates varied notably among patients based on their Fcγ receptor polymorphism status.
Findings suggest potential for tailoring neuroblastoma treatments based on genetic profiles to improve outcomes.

Implication

Observational analysis shows event-free and overall survival differ in patients based on Fcγ receptor polymorphism, indicating treatment response nuances.

Abstract

Supplementary Figure S5. Event-free survival and overall survival in HACA-positive and HACA-negative patients (A and B) and by dinutuximab beta exposure of above and below median AUC (C and D). AUC, area under the curve; EFS, event-free survival; HACA, human anti-chimeric antibodies; OS, overall survival; SE, standard error.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lode et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd028a5 https://doi.org/10.1158/1078-0432.30028886

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S5 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S5 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers